EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
·
2018
·
IF 3.466
Qi Liu,Wei-Wei Ni,Zhen Li,Cai-Fu Bai,Dan-Dan Tan,Chang-Jun Pu,Dong Zhou,Qing-Peng Tian,Ni Luo,Kai-Li Tan,Le Dai,Yuan Yan,Yong Pei,Xian-Hui Li,Zhu-Ping Xiao,Hai-Liang Zhu
The continuing emergence of drug-resistant Helicobacter pylori (HP) drives the ongoing need for the development of new and effective anti-HP drugs. Urease inhibitor has now gained strong interest as an alternative approach for HP infections . 3-Chlorophenyl-3-hydroxypropionylhydroxamic acid (CPH), a novel urease inhibitor identified in our group, shows impressive potency, which was optically separated for a further exploration. Here, we report in vitro / in vivo pharmacological evaluation of (±)-CPHs and the enantiomers. The raceme and the individual enantiomers significantly suppress gastritis at 32 mg/kg b.i.d dose with lower toxicity to mammalian cells (with CC 50 s ≥ 3.16 mM) and mice (LD 50 s ≥ 2338 mg/kg) than the clinically used agent acetohydroxamic acid . Furthermore, a significant increase of eradication of HP is observed for the combination of (±)-CPHs or the enantiomers with an antimicrobial. These studies revealed that CPH is a promising candidate for an alternative treatment of HP-dependent conditions by targeting virulence factor urease, and CPH may be used as a raceme.
✓ 已验证
DOI
PubMed
高影响因子
ELECTROCHIMICA ACTA
·
2025
·
IF 5.6
Xiying Tang,Le Guo,Wenli Qiao,Leina Jia,Wenming Jin,Xinsheng Liu,Yonghong Li
A label-free Helicobacter pylori ( H. pylori ) VacA antibody immunosensing platform based on silver nanoparticles doped reduced graphene oxide/ionic liquid composites electrode (Ag@rGO/CILPE) was successfully prepared. Ag@rGO/IL nanocomposites not only enhanced the immobilization capacity for VacA antigen but also improved the response signal of the immunosensor, it could achieve selective recognition for VacA antibody. The linear range of VacA antibody was 0.01-1 ng mL -1 using the proposed method, with a detection limit of 5 pg mL -1 . The constructed immunosensor had good specificity, reproducibility, and stability. It could be used for the determination of VacA antibody in human serum samples, achieving the typing diagnosis of H. pylori infection.
✓ 已验证
产品关联
DOI
高影响因子
Journal of Functional Foods
·
2025
·
IF 4
Shuyi Sang,Chuqiu Zhang,Bingyun Lu,Yuanjing Zou,Chang Peng,Yuqian Lai,Meicun Yao,Ye Chen,Qingchang Chen
Helicobacter pylori (H. pylori) infection affects over half of the global population, leading to chronic gastritis, gastric ulcers and cancer. Traditional antibiotic therapies face challenges such as resistance and gut microbiota dysbiosis, necessitating alternative solutions. Qi-Fu-Qing-You (QFQY) formulation was developed using medicinal and edible plants. This study investigated its anti- H. pylori efficacy, active components, and mechanisms of action. Phytochemical analysis revealed bioactive compounds such as ellagic acid, gallic acid, and psoralen, which demonstrated significant antibacterial activity against both antibiotic-sensitive and -resistant H. pylori strains. Molecular dynamics simulations showed that these compounds bind to the allosteric site of penicillin-binding protein 1 A (PBP1A), enhancing antibiotic binding affinity and improving antibacterial efficacy. In vivo studies confirmed QFQY's ability to mitigate antibiotic-induced intestinal damage through anti-inflammatory and anti-apoptotic effects, maintaining gut microbiota balance. The results underscore QFQY's potential as a functional food for H. pylori management and as an adjunct to antibiotic therapies.
✓ 已验证
产品关联
DOI
高影响因子
FITOTERAPIA
·
2025
·
IF 2.6
Shiyuan Huang,Xu Wang,Jingjing Zhao,Zhidi Wu,Suqing Zhao
Amomum villosum Lour. ( A. villosum ), a renowned traditional Chinese medicine, is extensively utilized in China for treating gastrointestinal diseases. A. villosum essential oil (AVEO) has been shown to impact gastric cancer cell apoptosis, yet its inhibitory effect on Helicobacter pylori (Hp) and therapeutic efficacy in gastrointestinal disorders remain uninvestigated. To address this gap, this study integrates network pharmacology and in vitro experiments to analyze AVEO's composition and anti-Hp potential. AVEO extracted via steam distillation was subjected to GC–MS analysis, identifying camphor (39.697 %), bornyl acetate (16.459 %), limonene (10.367 %), camphene (7.351 %), and borneol (6.46 %) as major components. Subsequently, a “Compounds-Drug-Targets” network was constructed and enriched using Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). Molecular docking predicted strong binding affinity between AVEO components and Hp targets. Experimentally, AVEO exhibited a minimum inhibitory concentration (MIC) of 256 μg/mL against Hp, disrupting biofilm formation and delaying its logarithmic growth phase. Furthermore, fractional inhibitory concentrations (FIC) assays revealed additive effects when AVEO was combined with antibiotics (Metronidazole, Levofloxacin, Amoxicillin, and Clarithromycin). Collectively, network pharmacological and in vitro validation confirmed AVEO's multi-target, multi-pathway anti-Hp mechanism.
✓ 已验证
DOI
PubMed
高影响因子
CARBOHYDRATE POLYMERS
·
2025
·
IF 12.5
Xinyuan Zhang,Pei Xie,Yongkang Lai,Jiulong Zhao,Qiuping Gu,Yingfeng Wei,Zheng Chen,Liang Zhang,Shige Wang,Hongxin Sun,Chunping Zhu
Helicobacter pylori ( H. pylori ) is a globally prevalent bacterial pathogen associated with various gastrointestinal diseases, including gastritis, peptic ulcers, and gastric cancer. However, the effectiveness of oral medications is often compromised by the harsh gastric environment, leading to limited therapeutic outcomes. In this study, we developed a novel carboxymethyl chitosan/poly-γ-glutamic acid/polyvinyl pyrrolidone (CMCS/γ-PGA/PVP, CPP) sponge with a high swelling ratio and mechanical stability for gastric retention and targeted drug delivery. The CPP sponge demonstrated rapid swelling in acidic environments (38.16 g/g) and prolonged intragastric retention for up to 3 days while maintaining structural integrity under gastric peristalsis. Loaded with amoxicillin and ebselen, the CPP sponge significantly enhanced drug bioavailability and achieved a 98.59 % bacteriostasis ratio against H. pylori in a mouse model. Additionally, the sponge could alleviate gastric inflammation. The CPP sponge's triple-network structure, combining intramolecular amide bonds, intermolecular amide bonds, and hydrogen bonds, provided excellent mechanical stability and swelling properties. This study highlights the potential of the CPP sponge as an effective therapeutic platform for H. pylori infection, offering sustained drug release, improved gastric retention, and enhanced therapeutic efficacy.
✓ 已验证
产品关联
DOI
PubMed
高影响因子
TALANTA
·
2023
·
IF 6.1
Yilu Wang,Qiming Chen,Yingying Wang,Fangmin Tu,Xiaodi Chen,Junhai Li,Zhanmin Liu
Helicobacter pylori ( H. pylori ) is a kind of microaerobic and food-borne pathogen. More than 4.4 billion individuals have been infected by H. pylori and H. pylori was listed as Group I carcinogen by WHO in 1994. Considering the high infection rate of H. pylori and the limited medical resources, self-testing is helpful for diagnosis and timely treatment. Although the amount of H. pylori in human saliva is low, the sampling of saliva is simple and convenient compared with stomach, blood and stool samples. Therefore, H. pylori in human saliva can be an indicator for self-testing, and a sensitive and easy-to-use assay is necessary. In this study, we developed a time-resolved fluorescent microsphere-lateral flow immunoassay (TRFM-LFIA) strip assay with image visual analysis for detection of H. pylori in saliva. The detection of the TRFM-LFIA strip was easy to use and had a low dependency on equipment. With optimized preparation and detection parameters, the whole detection process could be finished in 8 min and the LOD by naked eyes was 10 2 CFU/mL. For quantitative analysis by image visual analysis, the LOD was as low as 1.05 CFU/mL in the linear range of 10 1 –10 5 CFU/mL. Besides, the TRFM-LFIA strip also had good stability, reliability, repeatability and accuracy. All these advantages indicated that the TRFM-LFIA strips developed in this study had a good potential for self-testing for H. pylori infection.
✓ 已验证
产品关联
DOI
PubMed
高影响因子
Advanced Materials Technologies
·
2024
·
IF 6.4
Anran Li,Ke Zhang,Zhijun Wang,Siyuan Liu,Xiaofei Li,Jianbing Ren,Jianjun Zhang,Yunyi Shi,Yuan Gao,Shuai Qian,Yuanfeng Wei
Currently, standard quadruple therapy is the primary treatment for Helicobacter pylori infection; however, compliance is low due to its complicated dose regimen. 3D-printed combination tablets offer a promising strategy to simplify dose regimens due to their flexible structure. However, it is difficult to print combination tablets with a single printing technique because of the different physicochemical properties of the drugs. In this study, a hybrid deposition modeling (HDM) 3D printer is developed for the first time, concentrating the advantages of fused deposition modeling technology and semi-solid extrusion technology, to prepare “rocket-separated” combination tablets containing four drugs with different release behaviors. In 0.1 m HCl medium (mimicking gastric environment), the interlayer of the tablet containing bismuth potassium citrate erodes within 5 min, then the top and bottom layers separate, with the top one floating up to the surface of the medium, starting to release metronidazole and doxycycline after 1.5 h, the omeprazole enteric bottom layer releases in PBS 6.8 medium (mimicking intestinal environment) within 2 h. Overall, this combination tablet is suitable for actual clinical needs and avoids the chance of missed or wrong dosing. Moreover, HDM technology opens the door for future integration of multiple technologies in 3D printing formulations.
✓ 已验证
产品关联
DOI
高影响因子
JOURNAL OF FOOD SCIENCE
·
2024
·
IF 3.2
Shirui Zhai,Yinyin Gao,Yiru Jiang,Yuwan Li,Qiuxia Fan,Shanshan Tie,Ying Wu,Shaobin Gu
Helicobacter pylori is a highly prevalent pathogen in human gastric mucosa epithelial cells with strong colonization ability. Weizmannia coagulans is a kind of active microorganism that is beneficial to the improvement of host gut microbiota balance and can prevent and treat intestinal diseases. We investigated the beneficial effects of W. coagulans BC99 in H. pylori infected mice and measured inflammation response, oxidative stress, and gut microbiota. Results showed that BC99 could alleviate the gastric inflammation, inhibit the increasing of inflammation parameters endotoxin, interleukin-10, transforming growth factor-β, and interferon-γ and oxidative stress myeloperoxidase and malondialdehyde, promote the levels of superoxide dismutase and catalase. Furthermore, 16S rRNA gene sequencing analysis revealed that BC99 reversed the change of gut microbiota by reducing the abundance of Olsenella , Candidatus _ Saccharimonas , Monoglobus , and increasing the abundance of Tyzzerella . Meanwhile, BC99 caused elevated levels of Ligilactobacillus and Lactobacillus . In view of the beneficial effect of BC99 on the content of short-chain fatty acid, valeric acid with sodium valerate interfered with H. pylori infection in mice found that valeric acid had a good restorative effect of H. pylori infection relating inflammation and oxidative stress responses. These results suggest that W. coagulans BC99 can be used as a potential probiotic to prevent and treat H. pylori infection by regulating the inflammation, oxidative stress, and gut microbiota.
✓ 已验证
产品关联
DOI
PubMed
高影响因子
JOURNAL OF ETHNOPHARMACOLOGY
·
2026
·
IF 6.8
Ling Ou,Bingyun Lu,Zhong Feng,Haobo Chen,Yuanjing Zou,Chuqiu Zhang,Qingchang Chen,Chang Peng,Meicun Yao,Ye Chen
Ethnopharmacological relevance Helicobacter pylori ( H. pylori ) infection is a leading risk factor for chronic gastritis, peptic ulcers, and gastric cancer. The escalating antibiotic resistance of H. pylori and adverse effects arising from standard antibiotic regimens have underscored an urgent need for natural, food-complementary therapeutic alternatives. Terminalia chebula Retz., commonly named “Hezi” in traditional Chinese medicine and “Haritaki” in Ayurveda, is a well-recognized edible fruit with a long history of use in alleviating gastrointestinal disorders. Aim of the study While it has been traditionally recognized for its anti-inflammatory and antimicrobial properties, its anti-adhesive efficacy against H. pylori and the metabolic mechanisms underlying its in vivo effects remain largely unexplored. Materials and methods This study adopted multiple analytical and experimental approaches: ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), RNA-seq, cell viability and adhesion assays, western blotting, hematoxylin and eosin (H&E) staining, enzyme-linked immunosorbent assay (ELISA), metabolomics, and proteomics. Results In this study, 15 primary compounds in T. chebula aqueous extract were identified, predominantly tannins. Multi-omics analyses (transcriptomics, metabolomics, and proteomics) revealed that T. chebula aqueous extract significantly inhibited H. pylori adhesion and enriched the lysine degradation pathway. Notably, N-alpha-acetyl-L-lysine was characterized as a key metabolite in fecal metabolomic profiling, which was associated with glycosphingolipid biosynthesis, ferroptosis, HIF-1 signaling, lysosomal function, and arginine metabolism. In vitro assays confirmed that N-alpha-acetyl-L-lysine reduced H. pylori adhesion to GES-1 cells, reversed H. pylori -induced cellular damage, and suppressed the secretion of pro-inflammatory cytokines (IL-6 and TNF-α). In vivo , T. chebula aqueous extract administration markedly alleviated H. pylori -induced gastric inflammation by downregulating IL-6, IL-1β, TNF-α, TGF-β, and IFN-γ. Collectively, these findings demonstrate that T. chebula aqueous extract exerts anti- H. pylori effects by regulating lysine metabolism, with N-alpha-acetyl-L-lysine serving as a key metabolite via fecal metabolomics. Conclusion These findings highlight T. chebula 's promising potential as a functional food ingredient or adjunctive therapy for H. pylori -related diseases, providing a natural, mechanism-based option for clinical intervention.
✓ 已验证
产品关联
DOI
高影响因子
Acta Pharmaceutica Sinica B
·
2026
·
IF 14.6
Xiaonan Chen,Yuhan Fan,Jiabao Hao,Shuqi Zhang,Suqi Hao,Yingying Sun,Jing Li,Ling Zhang,Shihui Yu,Haiyan Hu
Helicobacter pylori ( H. pylori ) infection disrupts the gastric microenvironment and promotes the development of gastric cancer and other gastrointestinal diseases. Despite the high prevalence of asymptomatic chronic infection and recurrent infections, persistent mucosal injury continues to drive early pathological alterations, including gastric epithelial remodeling and intestinal metaplasia, that may become irreversible beyond a “point of no return”. Although clinical antibiotic-based H. pylori eradication therapies reduce gastric cancer risk, their efficacy markedly diminishes once progressive gastric premalignant lesions developed, and long-term use often causes microbiome dysbiosis and antimicrobial resistance. To address these unmet clinical needs, we developed CurE-gel, an antibiotic-free smart in situ gel with pH- and lipase-cascade responsive drug release. This system enables targeted eradication of H. pylori while simultaneously facilitating gastric niche restoration. Composed of sodium alginate and polyacrylate, CurE-gel exhibits strong gastric mucosal adhesion and precise pH responsiveness. Utilizing the pathophysiological gastric pH gradient (luminal pH 1–2 vs. mucosal pH>4), CurE-gel mediates unidirectional release of its encapsulated nanocapsules (CurE-cap) at damaged mucosal side. Then CurE-cap penetrated the mucus and accumulated at H. pylori colonies, where its polycaprolactone shell is hydrolyzed by bacterial lipase to release curcumin and eugenol. This system achieved: (i) targeted H. pylori eradication via biofilm disruption and virulence suppression; (ii) epithelial barrier protection and pathological progression suppression through virulence translocation inhibition, ROS scavenging, lipid peroxidation reduction and DNA damage mitigation; and (iii) gastric homeostasis restoration by recovery of tight junction proteins and gastric microbiota modulation. In vivo , CurE-gel achieved over 99% H. pylori eradication, reversed gastric progressive premalignant lesions and reconstructed a healthy gastric microbiota without systemic toxicity. Via integrating mucoadhesive retention, pH- and lipase-cascade responsive drug release, this platform sets an innovative paradigm for two-pronged strategy in targeted H. pylori clearance and gastric homeostasis restoration, ultimately aiming to prevent gastric carcinogenesis.
✓ 已验证
产品关联
DOI
高影响因子
IONICS
·
2024
·
IF 2.4
Qiao Wenli,Zhang Zhen,Tang Xiying,Chang Mengjun,Guo Le,Liu Xinsheng,Li Yonghong
Helicobacter pylori ( H. pylori ) can cause a variety of gastric diseases, such as chronic gastritis, gastric ulcer, intestinal metaplasia, and dysplasia, and eventually lead to gastric cancer. Therefore, it is crucial to achieve early diagnosis of H. pylori . The biosensing platform was constructed for Epitope Vaccine against Four Virulence Proteins from H. pylori (FVpE) based on chitosan (CS)@ionic liquid (IL) and graphitic carbon nitride (g-C 3 N 4 ) modified glassy carbon microspheres ionic liquid paste electrode. The results showed that the substrate electrode had good electrical conductivity, which could amplify the response signal and improve the detection sensitivity. The developed immunosensor exhibited good immunoreactivity for H. pylori antibodies with wide linear range (0.05–5 ng mL −1 ) and low detection limit (0.01 ng mL −1 ). In addition, the electrochemical immunosensor presented quick response, high sensitivity, good specificity, and stability. The immunosensor could be used to detect H. pylori in serum samples with recoveries between 99 and 112%. It can provide a theoretical basis for the development of label-free electrochemical H. pylori immunosensors.
✓ 已验证
产品关联
DOI
高影响因子
TALANTA
·
2026
·
IF 6.7
Jie Zan,Wenjie Guo,Wencheng Tan,Jieying Lan,Tianxu Li,Yongyu Huang,Rui Feng,Aoxue Gao,Chen Wang,Lei Gao,Zhiming Wu,Chaozhan Chen
Current diagnostic methods for Helicobacter pylori ( H. pylori ) infection suffer from critical limitations. Endoscopy is invasive, while stool antigen tests and urea breath tests require specialized laboratories and complex sample processing. To address these unmet needs, we present a novel saliva-based point-of-care platform for rapid and quantitative H. pylori detection. The platform consists of two innovative biosensors: a time-resolved fluorescent microsphere-lateral flow immunoassay strip (TRFM-LFIA) and an electrochemical immunosensor, specifically designed for UreB antigen detection in unprocessed saliva. A high-affinity monoclonal antibody pair (2-C2-F5/8-B5-E6) targeting non-overlapping UreB epitopes was developed through integrated recombinant antigen expression, hybridoma technology, and molecular docking. This antibody pair was applied to both biosensors using a double-antibody sandwich format, achieving high sensitivity (LOD: 91 pg/mL for TRFM-LFIA; 38.3 pg/mL for electrochemical immunosensor) and broad dynamic range (0.1–1000 ng/mL) without sample pre-treatment. Both biosensors demonstrated good specificity against common interferents, with reproducibility below 8% coefficient of variation, and 100% concordance with gold-standard diagnostics in 21 saliva samples (11 H. pylori -positive, 10 healthy controls). Crucially, this work enables direct saliva analysis, eliminating the need for invasive procedures and complex infrastructure, thereby offering a scalable and cost-effective solution for resource-limited settings.
✓ 已验证
DOI
PubMed
高影响因子
危险品化学品经营许可证（带存储）